Categorizing the response to Epoetin alfa therapy. Case study of the anemic patient.
Hyporesponse to Epoetin alfa therapy can be minimized by categorizing patients on the basis of trends in hemoglobin/hematocrit levels and initiating a continuous quality improvement effort that focuses on subnormal outcomes. An algorithm is provided that clinicians can use to proactively assess common causes that contribute to hyporesponse and limit the effect on patient outcomes.
Watson
C
C
Amgen Inc., Thousand Oaks, CA, USA.
D000465:Algorithms; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000209:etiology* / Q000523:psychology / Q000628:therapy*; D003663:Decision Trees; D016903:Drug Monitoring / Q000379:methods*; D004921:Erythropoietin / Q000627:therapeutic use*; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D009730:Nursing Assessment / Q000379:methods*; D011788:Quality of Life; D017749:Total Quality Management / Q000458:organization & administration*
D006454:Hemoglobins; D004921:Erythropoietin